Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel
October 20, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
October 14, 2020 17:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
September 10, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update
August 12, 2020 16:01 ET
|
Neoleukin Therapeutics, Inc.
NL-201 IND submission anticipated during fourth quarter of 2020Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023Company to...
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
August 06, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020
August 05, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering
July 02, 2020 09:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Proposed Public Offering
July 01, 2020 16:01 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
June 22, 2020 09:05 ET
|
Neoleukin Therapeutics, Inc.
- NL-201 demonstrates durable antitumor activity in animal tumor models -- NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo -- Conditional activation of de novo...